SHR-4610 injection for advanced solid tumors
Official title: An Open-label, Multicenter Phase I/II Clinical Study of SHR-4610 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy
Run by Shanghai Shengdi Pharmaceutical Co., Ltd · NCT07231211 · Data updated 2026-11-12
This trial will test SHR-4610 injection to see if it helps adults (18–75) with unresectable or metastatic solid tumors that have not responded to standard treatments.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 258 (estimated) |
| Sponsor | Shanghai Shengdi Pharmaceutical Co., Ltd Industry-sponsored |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | November 20, 2025 |
| Main results expected | October 2026 |
| Study ends | December 2027 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT07231211 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors that are relapsed/refractory to standard therapies or lack standard treatments, with measurable disease, ECOG 0–1, and adequate organ function are the intended participants.
✕Probably not a fit
Patients with active central nervous system or meningeal metastases, uncontrolled significant cardiovascular disease, moderate/severe symptomatic effusions or ascites, active hepatitis B or C, or recent systemic anticancer therapy may not benefit or may be ineligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label, multicenter Phase 1/2 trial is organized into a dose exploration stage (dose escalation and dose extension) followed by an efficacy extension stage. Participants receive SHR-4610 by injection while investigators monitor safety and tolerability and identify a recommended dose. The dose-escalation phase determines safety and dose-limiting toxicities, and extension cohorts evaluate preliminary anti-tumor activity at selected doses. Eligible patients have histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors, measurable disease per RECIST v1.1, ECOG 0–1, and adequate organ function.
Why it matters
Potential benefit: If successful, SHR-4610 could become a new treatment option that shrinks tumors or controls disease in some patients with advanced, treatment-resistant solid tumors.
How similar studies have gone: Early-phase dose-escalation programs for novel oncology injections have sometimes led to later effective therapies in specific tumor types, but SHR-4610's clinical effectiveness has not yet been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form; 2. Age range: 18-75 years old, both male and female are welcome; 3. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment; 4. Have at least one measurable tumor lesion per RECIST v1.1; 5. ECOG performance status of 0-1; 6. Life expectancy ≥ 12 weeks; 7. Adequate bone marrow and organ function. Exclusion Criteria: 1. Patients with active central nervous system metastases or meningeal metastases; 2. Systemic antitumor therapy was received 4 weeks before the start of the study; 3. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion; 4. Have poorly controlled or severe cardiovascular disease; 5. Subjects with active hepatitis B or active hepatitis C; 6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.
Where it's running
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Yunpeng Jin
- Email: yunpeng.jin.yj1@hengrui.com
- Phone: +86-021-61053363
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
-
ONO-7429 in advanced or recurrent solid tumors
This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.